Abstract:Abstract It has been widely acknowledged that anti-Müllerian hormone (AMH) is a golden marker of ovarian reserve. Declined ovarian reserve (DOR), based on experience from reproductive-aged women, refers to both the quantitative and qualitative reduction in oocytes. This view is challenged by a recent study clearly showing that the quality of oocytes is similar in young women undergoing IVF cycles irrespective of the level of AMH. However, it remains elusive whether AMH indicates oocyte quality in women with advanced age (WAA). The aim of this study was to investigate this issue. In the present study, we retrospectively analysed the data generated from a total of 492 IVF/ICSI cycles (from January 2017 to July 2020), and these IVF/ICSI cycles contributed 292 embryo transfer (ET) cycles (from June 2017 to September 2019, data of day 3 ET were included for analysis) in our reproductive centre. Based on the level of AMH, all patients (= > 37 years old) were divided into 2 groups: the AMH high (H) group and the AMH low (L) group. The parameters of in vitro embryo development and clinical outcomes were compared between the two groups. The results showed that women in the L group experienced severe DOR, as demonstrated by a higher rate of primary diagnosis of DOR, lower antral follicle count (AFC), higher level of basal follicle stimulating hormone (FSH) and cancelation cycles, lower level of E2 production on the day of surge, and fewer oocytes and MII oocytes retrieved. Compared with women in the H group, women in the L group showed slightly reduced top embryo formation rate but a similar normal fertilization rate and blastocyst formation rate. More importantly, we found that the rates of implantation, spontaneous miscarriage and livebirth were similar between the two groups, while the pregnancy rate was significantly reduced in the L group compared with the H group. Further analysis indicated that the higher pregnancy rate of women in the H group may be due to more top embryos transferred per cycle. Due to an extremely low implantation potential for transfer of non-top embryos from WAA (= > 37 years old) in our reproductive centre, we assumed that all the embryos that implanted may result from the transfer of top embryos. Based on this observation, we found that the ratio of embryos that successfully implanted or eventually led to a livebirth to top embryos transferred was similar between the H and the L groups. Furthermore, women with clinical pregnancy or livebirth in the H or L group did not show a higher level of serum AMH but were younger than women with non-pregnancy or non-livebirth. Taken together, this study showed that AMH had a limited role in predicting in vitro embryo developmental potential and had no role in predicting the in vivo embryo developmental potential, suggesting that in WAA, AMH should not be used as a marker of oocyte quality. This study supports the view that the accumulation of top embryos via multiple oocyte retrieval times is a good strategy for the treatment of WAA.

Predictive value of AMH combined with age for IVF-ET outcomes

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

The Role of Serum AMH and FF AMH in Predicting Pregnancy Outcome in the Fresh Cycle of IVF/ICSI: a Meta-Analysis.

Correlation analysis of baseline antimullerian hormone level and clinical pregnancy rate in advanced age patients with frozen-thawed embryo transfer

The Predictive Levels of Serum Anti-Müllerian Hormone and the Combined Index of the Number of Retrieved Oocytes and Good-Quality Embryos in Advanced-Age Infertile Women.

Predictive Value of the Serum Anti-Müllerian Level for Spontaneous Pregnancy in Women after Endometriosis Surgery

Higher Serum AMH Level is Associated with Better Pregnancy Outcomes of IVF/ICSI Assisted Pregnancy in Infertile Patients under 35 Years Old.

IVF Outcomes of Women with Discrepancies Between Age and Serum Anti-Müllerian Hormone Levels.

The Association of AMH Level with the Number and Quality of Oocytes in Women Undergoing IVF/ICSI: A Single-Center Study

High anti-Mullerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment

Serum Levels of Anti-Müllerian Hormone Influence Pregnancy Outcomes Associated with Gonadotropin-Releasing Hormone Antagonist Treatment: a Retrospective Cohort Study

High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment

Correlation Analysis of Baseline Antimullerian Hormone Level and Live Birth Rate of FreshEmbryo Transfer Cycles and Frozen Embryo Transfer Cycles

Analysis of cumulative outcomes and influencing factors of patients with discrepancies between age and AMH levels in the early follicular phase prolonged protocol

Prediction of Pregnancy Outcome of ART by AMH: A Meta-analysis

Serum anti-Müllerian hormone levels are associated with early miscarriage in the IVF/ICSI fresh cycle

Basal Serum Anti-Müllerian Hormone Level as a Predictor of Clinical Outcomes in Freezing-all Embryo Transfer Program

The Predictive Value of Anti-Mullerian Hormone on Pregnancy Rate After IVF

The Baseline Antimullerian Hormone (AMH) Level As an Independent Predictor of Live Birth Rate of Frozen-Thawed Embryo Transfers: a Multivariate Analysis of 828 Cycles

The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF

AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles